Diagnostics shares the same two key challenges as most of digital health. One, long sales cycles of 9-18 months into providers, often even longer for payors and pharma. Two, FDA approval that necessitates clinical trials and typically adds a couple years before the company can commercialize its product. But diagnostics has a high degree of some additional challenges. And let’s not dismiss the backlash that Theranos caused — much has been written about it, including the bestseller “Bad Blood.” This post offers a framework for how startups can tackle the beasts of recurrence, distribution and reimbursement — and still succeed…....
Why Diagnostics Is Hard: Three Extra Challenges And How Startups Can Still Succeed
2 min read
